| Cardiardiovascular dysfunction is prevalent in ESRD patients,and becomes risk factor to the survival and success of renal transplant. Lesion of myocardium caused by uremic environment is the primary cause of presenting of Cardiardiovascular dysfunction &diseases.These Cardiardiovascular dysfunction&diseases bring about more than 50% death in total uremic patients' death. And in renal transplant patients,me operation and postoperation drug administration and delaying of renal function recovery can further aggravate the lesion of myocardium and pump faction. So it's important to prevent the aggravation of the lesion of myocardium and maintain a stable heart pump function or even improve it.Control of Bp,EPO administration,control of hyperparathyroidism, hemodialysis and renal transplantion can partially cure the lesion of myocardium and improve heart pump function.Echocadiography is considered as a non-invasive and valuable method to valuate heart morphology and function.This study was performed to compare the heart size&function by echocardiography between uremic and normal people, before and after drug&hemodialysis therapy in uremic patients and before and after renal transplant,in order to know the pattern of cardiac lesion in uremic patients,and to know whether those therapy work or not,and what kind of improvement of heart morphology and function they could bring out.Methods:A opened,control 2-stage study was performed in uremic and normal people.Stage l:in this period,compare Bp,Hb and echocardiography of 66 uremic patients who have not began hemodialysis therapy or just began this therapy with those of 77 normal people,to know the pattern of morphologic and functional lesion of heart in uremic patients.Stage 2:compare Bp,Hb and echocardiography of 31 patients before and after drug and hemodialysis therapy for 4-8 months and 5 patients before and after renal transplant. Analyzing whether those therapy work or not,and what kind of improvement of heart morphology and function they could bring out.Results:1. There are 74.2%(24/35) male patients with LVH,and 14 were concentric hypertrophy,theother 10 were eccentric.While in female the ratio was 93.5%(29/31),and 19 were concentric hypertrophy, the other 10 were eccentric. Enhancement of myocardium echos was observed in 45.5%(30/66) patients,while valve reflu in 78.8%(52/66), pericardial effusion in 28.8%(19/66).2. Significant difference was observed in size of all chambers of heart, LVPWd, FVSd, LVM and LVMI between uremic and normal people (P0.01). All chambers of heart significantly enlarged while LVPWd,IVSd,LVM and LVMI increased in uremic people.No significant difference was observed in 1VPW and FVS movement between this 2 groups.3. Significant increase was observed in SV and CO in male uremic patients (P0.01), while no significant change in FS and EF. In female uremic patients,significant increase was observed in SV and CO (P<0.01),and significant decrease in EF (P<0.05). A peak significant increased in both male and female patients(P<0.01), while E/A significant decreased(P<0.01). No significant difference was observed in E peak.4. In stage 2,after strictly drug and hemodialysis therapy for 4 months,Bp significantly decreased, Hb significantly increased than baseline (P<0.01).5. If we group the hemodialysis patients by gender,we found in male patients there was no significant difference in size of all chambers of heart before and after drug and dialysis therapy,while significant decrease of LAD was observed in female patients.LVPWd and IVSd significantly decreased in male patients after average 5.8 months(P<0.05;P<0.01).While in female patients IVSd,LVM and LVMI significantly decreased(P<0.05).EF and FS significantly increased(P<0.01;P<0.05).Significant negative correlation was found between AHb and AIVSEDT in male patients (r=-0.453,P=0.043) .6. If we group the hemodialysis patients by pattern of LVH,we found LAD significantly decreased in concentric hypertrophic patients (P<0.05), and no significant differenc...
|
PDF Full Text Request